In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Adenosine Therapeutics LLC

Division of Allergan PLC
www.adenrx.com

Latest From Adenosine Therapeutics LLC

Kyowa Kirin Presses On With Parkinson's Prospect In US As Successor Readied

Some 12 years after first NDA submission, Kyowa Hakko Kirin tries again to secure US approval for troubled Parkinson's drug, but some analysts remain unsure of commercial potential and the company itself is progressing a successor.

United States Business Strategies

Corporate VC Adds a Business Development Flavor

Nearly all the meters on pharma's pipeline are reading critical. With licensing and M&A increasingly a series of high-priced auctions, Big Pharma is casting about, often desperately, for new business-development strategies. And one place they're beginning to look is corporate venture capital, traditionally a way to provide drug companies with a window on new technologies. But that means finding a way to break through the seemingly impenetrable wall between corporate venture investing and other corporate and research activities. Thus, companies have embarked on a number of different strategies, ranging from the traditional to the radically new and aggressive. Getting the equity investor and the asset-hungry pharma partner to co-exist peacefully has aroused plenty of both skepticism and confusion Nevertheless, there's still a promising way for drug companies to get value from start-ups beyond mere equity appreciation--investing de-prioritized drug candidates, not merely capital.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Biotechnology
  • In Vitro Diagnostics
  • Pharmaceuticals
  • Therapeutic Areas
  • Non-Specific
  • Alias(es)
  • Ownership
  • Private
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Allergan PLC
  • Senior Management
  • Robert S Capon, CEO
    William B Stilley, CFO & COO
    William S Gray, VP, Lic. & Sec'y
    Shannon P Williams, VP, Reg. & Clin. Dev.
  • Contact Info
  • Adenosine Therapeutics LLC
    Phone: (434) 220-9400
    P.O. Box 4632
    P.O. Box 4632 Charlottesville, VA 22905
    USA
Advertisement
Advertisement
UsernamePublicRestriction

Register